Ask HopeStage to review this study with me
Study ID: NCT06827431. We help you review the study, but cannot decide medical eligibility.
Not Yet RecruitingNCT06827431
Ammoxetine Hydrochloride Enteric-coated Tablets for depression
This study is not yet recruiting. It is testing Ammoxetine Hydrochloride Enteric-coated Tablets for depression.
DepressionDrugFrom 18 Years to 65 Years
The public registry lists this study as not yet recruiting. Check the official record and ask the research team when recruitment may open.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
No specific site is confirmed in the available information. Check the official source for locations and remote participation.
Key information made simple
What is this study testing?
This study is testing whether Ammoxetine Hydrochloride Enteric-coated Tablets may be useful for adults experiencing depression.
What would participation involve?
Participants may receive Ammoxetine Hydrochloride Enteric-coated Tablets, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Participation locations and format are not confirmed in the available information. Ask the research team to confirm the location, any in-person visits, time commitment, costs or compensation, and participation criteria.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateEstimated: February 14, 2025
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 770
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06827431
- Official title
- Efficacy and Safety of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression: A Multicenter, Randomized, Double-blind, Double-Dummy, Placebo-controlled and Sertraline Active-controlled, Parallel-group, Phase III Study
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT06827431. We help you review the study, but cannot decide medical eligibility.
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Confirm the location and whether remote participation is possible with the research team.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Ammoxetine, Placebo, Sertraline. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., which appears to be a pharmaceutical company. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not yet recruiting. Check the official record and ask the research team when recruitment may open.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Not Yet RecruitingNCT07062666
A Multicentre Clinical Study
This study is not yet recruiting. It focuses on depression and currently lists study information.
Not Yet RecruitingNCT03833206
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
This study is not yet recruiting. It focuses on depression and currently lists study information in the United States.
Not Yet RecruitingNCT07227103
Randomized, Double-Blind Controlled Comparison of NRX-101 for treatment-resistant depression
This study is not yet recruiting in the United States. It is testing Randomized, Double-Blind Controlled Comparison of NRX-101 for treatment-resistant depression.